MS Briefs

High serum homocysteine levels in patients with MS


 

Key clinical point : Patients with multiple sclerosis (MS), particularly those with relapsing-remitting MS (RRMS) have higher serum levels of homocysteine (Hcy).

Major finding : The MS group had higher serum levels of Hcy (standardized mean difference [SMD], 0.64; P less than .0001) compared with the control group. There were no significant differences in levels of vitamin B12 (SMD, –0.08; P = .58) or folate (SMD, 0.07; P = .52) between the MS and control groups. There was a statistically significant difference for Hcy between patients with RRMS and control individuals (SMD, 0.67; P = .004) but not between patients with primary or secondary progressive MS and control individuals.

Study details : A meta-analysis of 21 studies, including 1,738 patients with MS and 1,424 control individuals.

Disclosures: The study was supported by the National Natural Science Foundation of China and the Beijing Municipal Administration of Hospitals Incubating Program. The authors declared no conflicts of interest.

Citation: Li X et al. Int J Med Sci. 2020 Mar 5. doi: 10.7150/ijms.42058 .

Recommended Reading

Multidisciplinary rehabilitation can improve highly impacting symptoms of relapse-onset MS
ICYMI Multiple Sclerosis
Cannabis use among patients with MS and spasticity
ICYMI Multiple Sclerosis
Vitamin D levels tied to clinical and radiological outcomes in early relapsing MS
ICYMI Multiple Sclerosis
Concussion in adolescents tied to MS risk
ICYMI Multiple Sclerosis
Elevated leptin levels linked with MS risk
ICYMI Multiple Sclerosis
Does diet quality influence late-onset MS risk?
ICYMI Multiple Sclerosis
N-acetyl cysteine may positively affect cerebral glucose metabolism in MS
ICYMI Multiple Sclerosis
FDA approves ozanimod for relapsing and secondary progressive forms of MS
ICYMI Multiple Sclerosis
MS: Trends in the use of disease-modifying agents
ICYMI Multiple Sclerosis
Cancer risks with biological therapies for MS
ICYMI Multiple Sclerosis